Article
Daiichi Sankyo to Develop Thrombus Dissolving Agent
Author(s):
Daiichi Sankyo signed an exclusive licensing agreement with clinical-stage biopharmaceutical company Translational Sciences to develop and commercialize its novel thrombus (blood clot) dissolving agent, TS23.
Daiichi Sankyo signed an exclusive licensing agreement with clinical-stage biopharmaceutical company Translational Sciences to develop and commercialize its novel thrombus (blood clot) dissolving agent, TS23, which is currently being studied in Phase I clinical trials.
“Daiichi Sankyo recognized the great potential of this novel therapy,” said Guy Reed, CSO/CEO of Translational Sciences, in a press release. “We believe they have the expertise and resources to fully develop it for the millions of patients each year who suffer cardiovascular disease and stroke. We are enormously grateful to the National Institutes of Health who provided crucial support to translate this research into therapy.”
Source: Daiichi Sankyo
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
